Division of Cardiology, Department of Medicine, Duke University Medical Center, Room 128A Hanes House, 330 Trent Drive, Durham, NC 27710, USA.
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, 12605 E. 16th Avenue, Aurora, CO 80045, USA.
Cardiol Clin. 2022 Feb;40(1):1-12. doi: 10.1016/j.ccl.2021.08.001.
Pulmonary arterial hypertension is characterized by obliteration and obstruction of the pulmonary arterioles that in turn results in high right ventricular afterload and right heart failure. The pathobiology of pulmonary arterial hypertension is complex, with contributions from multiple pathophysiologic processes that are regulated by a variety of molecular mechanisms. This nature likely explains the limited efficacy of our current therapies, which only target a small portion of the pathobiological mechanisms that underlie advanced disease. Here we review the pathobiology of pulmonary arterial hypertension, focusing on the systemic, cellular, and molecular mechanisms that underlie the disease.
肺动脉高压的特征是肺小动脉闭塞和阻塞,这反过来导致右心室后负荷增加和右心衰竭。肺动脉高压的病理生物学非常复杂,多种病理生理过程的参与受多种分子机制的调节。这种特性可能解释了我们目前的治疗方法效果有限的原因,这些方法仅针对导致晚期疾病的一小部分病理生物学机制。在这里,我们回顾肺动脉高压的病理生物学,重点介绍导致该疾病的系统、细胞和分子机制。